Description

Description: Safely explore increased transmissibility and other features of the spike protein from the CDC variant of concern SARS-CoV-2 Delta (B.1.617.2)Based on SBI’s popular and highly cited pPACKH1 Packaging System

Uses codon-optimized SARS-CoV-2 “S” protein from variant Delta (B.1.617.2, originally found in India) in place of VSV-G envelope protein

Spike protein mutations are T19R, G142D, ΔE156-157, R158G, L452R, T478K, D614G, P681R, D950NIdeal for vaccine and antiviral efficacy studies under BSL2 conditions

Package any 3rd-generation lentivector reporter of your choice, including SBI’s popular Lenti Labeler reporters Overview Safely study the spike protein from emerging SARS-CoV-2 variants

Potentially more transmissible than previous SARS-CoV-2 variants, the Delta variant (B.1.617.2) is classified as a variant of concern by the Centers for Disease Control (CDC) in the United States. This variant was initially observed in India and has since spread globally. With the pPACK-SPIKE™ Delta (B.1.617.2) Variant Spike Protein Lentivector Packaging Mix, you can safely characterize the SARS-CoV-2 S1 spike protein from lineage Delta (B.1.617.2), which contains the following mutations:T19RG142DΔE156-157R158GL452RT478KD614GP681RD950NDesigned to efficiently package most third-generation lentivectors, the pPACK-SPIKE Delta (B.1.617.2) Variant Spike Protein Lentivector Packaging Mix speeds and simplifies preparation of lentiviral particles pseudotyped with the SARS-CoV-2 T19R, G142D, ΔE156-157, R158G, L452R, T478K, D614G, P681R, D950N spike glycoprotein, making it an ideal reagent for vaccine and antiviral drug discovery projects. Based on SBI’s highl cited pPACKH1 packaging system but with a truncated T19R, G142D, ΔE156-157, R158G, L452R, T478K, D614G, P681R, D950N Spike protein [1] replacing the standard VSV-G envelope protein, the pPACK-SPIKE Delta (B.1.617.2) Variant Spike Protein Packaging Mix consists of three plasmids that produce all of the structural and replication proteins needed to transcribe and package an RNA copy of an expression lentivector into recombinant, T19R, G142D, ΔE156-157, R158G, L452R, T478K, D614G, P681R, D950N “Spike” pseudotyped lentiviral particles. As a result, you can conduct a range of SARS-CoV-2 studies under BSL-2 conditions, including neutralization assays, studies of virus interactions with host surface proteins, and the development of vaccines and therapeutics. For added convenience we also offer pPACK-BALD™, an envelope protein-free lentivector packaging mix that can be used as a negative control for any pPACK-SPIKE study, or for creating lentivirus particles pseudotyped with the envelope protein of your choice. Based on SBI’s popular and highly cited pPACKH1 Packaging System

Uses codon-optimized SARS-CoV-2 “S” protein from variant Delta (B.1.617.2, originally found in India) in place of VSV-G envelope proteinSpike protein mutations are T19R, G142D, ΔE156-157, R158G, L452R, T478K, D614G, P681R, D950NIdeal for vaccine and antiviral efficacy studies under BSL2 conditions

Package any 3rd-generation lentivector reporter of your choice, including SBI’s popular Lenti Labeler reporters

Compare with our full range of pPACK-SPIKE S protein pseudotyped lentiviruses to better understand emerging variants

Use with pPACK-BALD™, an envelope protein-free lentivector packaging system that is an ideal negative control pPACK-SPIKE Delta (B.1.617.2) Variant Spike Protein Lentivector Packaging Mix is available as stand-alone packaging mixes with sufficient plasmids for 10 reactions (standard size) or 25 reactions (XL), as well as in a convenient kit format that includes PureFection™ Transfection ReagentandPEG-it Virus Precipitation Solution."